Search

Editas Medicine Inc

Lezárt

SzektorEgészségügy

2.92 3.55

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

2.68

Maximum

2.88

Fő mutatók

By Trading Economics

Bevétel

6.8M

-18M

Értékesítés

9.1M

12M

Egy részvényre jutó nyereség

-0.15

Profit margin

-153.322

Munkavállalók

87

EBITDA

3.9M

-20M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+112.96% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 9.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

14M

421M

Előző nyitás

-0.63

Előző zárás

2.92

Hangulat hírek alapján

By Acuity

43%

57%

97 / 339 Rangsor szerint Healthcare

Editas Medicine Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 21. 21:51 UTC

Editas Medicine Inc is trading higher in after-market hours, recovering from significant volatility, but remains 2.00% below its 20-day moving average.

2026. szept. 18. 21:51 UTC

Editas Medicine Inc is advancing in after-market trading, moving higher alongside the broader market amid macroeconomic concerns and geopolitical tensions.

2026. szept. 17. 23:01 UTC

Editas Medicine Inc is higher in after-market trading, recovering from earlier lows, though it remains below its 20-day moving average.

2026. szept. 16. 20:07 UTC

Editas Medicine Inc is gaining in Wednesday's session, reflecting a positive trend since Tuesday's close, despite remaining below its 20-day moving average.

2026. szept. 15. 23:51 UTC

Editas Medicine Inc shares are higher in after-market trading. No specific company news was identified to explain this price movement.

2026. szept. 10. 20:08 UTC

Correlated Moves

Editas Medicine Inc shares are lower, extending a three-day decline amid broader biotechnology sector weakness and pressures from the European Central Bank's recent interest rate hike.

2026. szept. 9. 22:11 UTC

Editas Medicine Inc shares are higher in after-market trading, reflecting a notable increase since Wednesday's close, despite being below its 20-day moving average.

2026. szept. 8. 20:08 UTC

News

Editas Medicine appoints Dan Ory as Chief Medical Officer, shares decline sharply amid market response. The stock has reached a session low today.

2026. szept. 4. 23:02 UTC

Editas Medicine Inc shares are lower during after-market hours, reflecting a decline despite being above its 20-day moving average and near one-month highs.

2026. szept. 1. 19:16 UTC

News

Editas Medicine is participating in two investor conferences, enhancing visibility. Shares are higher today, reflecting positive investor interest in its CRISPR technology focus.

2026. aug. 31. 22:51 UTC

News

Editas Medicine has filed a prospectus for a $400 million mixed securities shelf offering, contributing to higher shares during after-market hours.

2026. aug. 28. 20:03 UTC

Editas Medicine Inc shares are lower today, retracing from earlier highs. Broader market dynamics, including rising Treasury yields, may be contributing to the decline.

2026. aug. 27. 23:02 UTC

Editas Medicine Inc is trading higher in after-market hours, reflecting positive sentiment since Thursday's close and resilience despite earlier session pullbacks.

2026. aug. 26. 23:16 UTC

Editas Medicine Inc shares are higher in after-market trading, positioned near the upper end of their one-month range and above the 20-day moving average.

2026. aug. 25. 19:21 UTC

Correlated Moves

Editas Medicine Inc is seeing gains during Tuesday's session, reaching a peak return earlier before pulling back slightly. Broader market sentiment remains favorable for biotech stocks.

2026. aug. 24. 22:22 UTC

Editas Medicine Inc shares are higher in after-market trading, showing some volatility. No specific news was identified to explain the price movement.

2026. aug. 21. 23:16 UTC

Editas Medicine Inc shares are lower in after-market trading. No specific news was identified to explain the decline, though the stock remains above its 20-day moving average.

2026. aug. 20. 23:46 UTC

Editas Medicine Inc is higher in after-market hours, gaining since Thursday's close. The stock is above its 20-day moving average amid no specific news.

2026. aug. 19. 23:21 UTC

Editas Medicine Inc. shares are lower in after-market hours, impacted by a decline in the Biotechnology sub-sector. No specific news was identified for the movement.

2026. aug. 17. 19:16 UTC

Editas Medicine Inc. shares are trading roughly flat amid overall market sentiment influenced by recent declines in U.S. retail sales and consumer sentiment.

2026. aug. 14. 22:21 UTC

Editas Medicine Inc is trading lower in after-market hours, continuing a decline over the past four sessions amid broader concerns over consumer demand.

2026. aug. 13. 21:32 UTC

Correlated Moves

Editas Medicine Inc advanced in after-hours trading, reflecting a shift in investor sentiment and aligning with a positive trend in the biotechnology sector.

2026. aug. 12. 19:31 UTC

Editas Medicine Inc shares are lower today, continuing a decline since Tuesday. No specific news has been identified to explain the drop.

2026. aug. 11. 19:46 UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

2026. aug. 10. 23:26 UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

2026. aug. 7. 23:16 UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

2026. aug. 6. 23:02 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

2026. aug. 5. 22:02 UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

2026. júl. 31. 19:56 UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

2026. júl. 30. 23:51 UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

Társak összehasonlítása

Árváltozás

Editas Medicine Inc Előrejelzés

Célár

By TipRanks

112.96% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 5.75 USD  112.96%

Magas 8 USD

Alacsony 4 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Editas Medicine Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

6 ratings

4

Vétel

1

Tartás

1

Eladás

Hangulat

By Acuity

97 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.